Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback